This is Part 2 of our series on LIS market consolidation. See Part 1 for background on the CliniSys-Orchard acquisition and its broader market implications.
Following CliniSys’s acquisition of Orchard Software, laboratory owners are asking how this might affect their operations. Industry research reveals consistent patterns when healthcare technology vendors are acquired, and understanding these challenges helps laboratories prepare proactive strategies to protect their interests.
When specialized vendors are absorbed into larger organizations, customers consistently report changes in several key areas that directly impact laboratory operations.
Industry surveys identify support quality as the most frequently affected area during vendor consolidations. Common changes include centralized support routing requests through general IT teams rather than clinical lab specialists, longer resolution times, and reduced direct access to technical experts familiar with your workflows. For laboratories accustomed to calling their account manager directly, these changes can significantly impact daily operations.
Consolidated vendors typically standardize processes, creating challenges for laboratories with unique requirements. This results in extended implementation timelines, reduced flexibility, higher customization costs, and complex approval processes for modifications that smaller vendors previously implemented quickly.
Academic research on market consolidation shows consistent patterns of price increases following acquisitions. Changes include standardized fees eliminating volume discounts, usage-based charges for previously included features, and annual increases tied to vendor growth targets. Studies of healthcare consolidation document price increases ranging from 11-54% in concentrated markets.
Large consolidated vendors face different development pressures, resulting in longer development cycles, reduced responsiveness to individual customer requests, and conservative approaches to new technologies.
The integration period provides Orchard customers with important opportunities to protect their interests, as customer leverage is typically highest during transition periods.
Even laboratories planning to stay with CliniSys benefit from understanding their options:
The CliniSys-Orchard acquisition represents a broader industry trend affecting laboratories regardless of their current LIS provider.
The consolidation trend makes vendor diversity increasingly valuable:
While vendor transitions create immediate challenges, they also provide opportunities to reassess LIS requirements and ensure technology partnerships support long-term laboratory success.
The key to navigating these transitions successfully lies in maintaining optionality while protecting current operations. Laboratories that take proactive steps during transition periods position themselves better regardless of how vendor integrations ultimately unfold.
The consolidation trend is accelerating, and forward-thinking laboratory owners are already taking action. Rather than waiting to see how vendor integrations unfold, many laboratories are proactively evaluating their options and making strategic moves to maintain operational independence.
We’re seeing an increasing number of laboratories choosing to transition to specialized, customer-focused LIS providers before consolidation forces their hand. These labs recognize that maintaining control over their technology partnerships is crucial for long-term success.
At Dendi, we’ve been helping laboratories navigate these transitions with transparent pricing, rapid implementation, and the personalized service that large consolidated vendors struggle to provide. Our customer-first approach has resonated with laboratory owners who want a true technology partner, not just a vendor.
Ready to explore your options? Contact Dendi today to learn how modern LIS technology and exceptional service can protect your laboratory’s future, regardless of what happens in the broader market.
Simplify. Integrate. Scale. Modernize your lab with Dendi today.